Marnix Goethals

Reclassification of patients with stage 2 or higher severe aortic valve stenosis based on left atrial reservoir strain

Ana Moyá, Emerson de Oliveira, Riet Dierckx, Marnix Goethals et autres

Abstract Introduction Survival following Transcatheter Aortic Valve Replacement (TAVR) is significantly influenced by the extent of extra-valvular cardiac damage at the time of the procedure. Génereux et al. introduced a staging system that classifies patients as stage 2 or higher if they …

it, be, br (code pays fourni par la source)

Deep learning for mortality prediction in patients with a de-novo or worsened heart failure

Robert Herman, Marc Vanderheyden, Boris Vavrik, Monika Beles et autres

Abstract Background Heart failure (HF) is a heterogenous syndrome with complex pathophysiology. Biomarkers and clinical risk scores often fail to provide optimal patient-level precision in the prognostic stratification. As utilizing single observational timepoint, they do not capture the entire care pathway with …

at, be (code pays fourni par la source)

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

Sean D. Pokorney, Jonathan Paul Piccini, Susanna R. Stevens, Manesh R. Patel et autres

BACKGROUND: Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. METHODS AND RESULTS: In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for …

us, de, au, gb (code pays fourni par la source)

Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin

Thitima Kongnakorn, Tereza Lanitis, Lieven Annemans, Vincent Thijs et autres

be (code pays fourni par la source)

Belgian Society of Cardiology Belgian Heart Rhythm Association (BeHRA)

Ivan Blankoff, Marnix Goethals, Georges H. Mairesse

Screening for atrial fibrillation in the general population: the optimal age limit. Results from the Belgian heart rhythm week 2010-2012

Georges H. Mairesse, Christophe Scavée, Nele Claes, Peter L.M. Goethals et autres

Diagnosing AF in patients aged 65 years (y) or over, before the first embolic complication, is recognized as a class I recommendation by the recent ESC guidelines. However, data are lacking in the general population to select the critical lower age limit …

Percutaneous Left Cardiac Sympathetic Denervation in a Patient With Long-QT Syndrome

W. Nagels, Steven Brabant, Lucas N. L. Van Aelst, Peter Pollet et autres

us (code pays fourni par la source)

Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting

Joris Kleintjens, Xiao Li, Steven Simoens, Vincent Thijs et autres

BACKGROUND: Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial fibrillation (AF). Recently, rivaroxaban, a novel oral anticoagulant (NOAC) which offers some distinct advantages …

be, de (code pays fourni par la source)

Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF

C E Chiang, Marnix Goethals, James O’Neill, Lisa Naditch‐Brûlé et autres

AIMS: International atrial fibrillation (AF) guidelines have defined optimal drugs for patients with various underlying diseases, but the extent to which real-life practice complies with these guidelines is unknown. This study aimed to evaluate the appropriate use of antiarrhythmic drugs (AADs) in …

tw, be, ie, fr, Tunisie, ua (code pays fourni par la source)

[Rivaroxaban: Xarelto--recommendations for pharmacists].

Jonathan Douxfils, Sébastien Michel, Christophe Beauloye, Marnix Goethals et autres

Rivaroxaban is one of the new oral anticoagulants (NOACs). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and …

be, jp, ru (code pays fourni par la source)

Rivaroxaban(Xarelto)®: Gids voor de apotheker

Jonathan Douxfils, Sébastien Michel, Christophe Beauloye, Marnix Goethals et autres

Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require …

Similar heart rates between atrial fibrillation and sinus rhythm in asymptomatic populations justify large scale screening to improve the detection of atrial fibrillation.

Georges H. Mairesse, Christophe Scavée, Nele Claes, Peter L.M. Goethals et autres

Purpose: Atrial fibrillation (AF) is known to be asymptomatic in up to 1/3 of patients. Early detection is however useful to prevent thrombo-embolic event. Since 2010, large awareness and screening campaigns are organized annually on a national level. Clinical characteristics of AF …